Minerva Neurosciences Inc
NERV1.940USD
+0.027+1.44%
Market hours （ET）Quotes delayed by 15 min
13.57MMarket Cap
2.17P/E TTM
More Details of Minerva Neurosciences Inc Company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
Company Info
Ticker SymbolNERV
Company nameMinerva Neurosciences Inc
IPO dateJun 25, 2014
CEODr. Remy Luthringer, Ph.D.
Number of employees8
Security typeOrdinary Share
Fiscal year-endJun 25
Address1601 Trapelo Road
CityWALTHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02451
Phone16176007373
Websitehttps://www.minervaneurosciences.com/
Ticker SymbolNERV
IPO dateJun 25, 2014
CEODr. Remy Luthringer, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Mr. Jan G. Van Heek
Mr. Jan G. Van Heek
Independent Director
Independent Director
--
--
Mr. Frederick Ahlholm, CPA
Mr. Frederick Ahlholm, CPA
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Mr. Jan G. Van Heek
Mr. Jan G. Van Heek
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
19.32%
Boehringer Ingelheim International GmbH
18.23%
The Vanguard Group, Inc.
3.60%
Luthringer (Remy)
2.64%
Renaissance Technologies LLC
1.63%
Other
54.57%
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
19.32%
Boehringer Ingelheim International GmbH
18.23%
The Vanguard Group, Inc.
3.60%
Luthringer (Remy)
2.64%
Renaissance Technologies LLC
1.63%
Other
54.57%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
24.51%
Corporation
18.23%
Individual Investor
4.02%
Hedge Fund
1.85%
Investment Advisor
1.64%
Research Firm
0.11%
Other
49.64%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
48
3.52M
50.36%
-225.80K
2025Q1
50
3.52M
50.36%
-205.49K
2024Q4
51
3.66M
52.27%
-624.23K
2024Q3
54
3.69M
57.40%
+418.43K
2024Q2
57
3.64M
56.76%
+303.74K
2024Q1
68
3.68M
57.33%
+358.05K
2023Q4
70
4.01M
62.11%
+650.59K
2023Q3
86
4.01M
62.11%
+311.12K
2023Q2
109
3.95M
71.07%
+754.34K
2023Q1
139
1.91M
35.70%
-1.35M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Federated Hermes Global Investment Management Corp.
1.35M
19.32%
--
--
Mar 31, 2025
Boehringer Ingelheim International GmbH
1.27M
18.23%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
252.06K
3.6%
--
--
Mar 31, 2025
Luthringer (Remy)
184.82K
2.64%
--
--
Mar 31, 2025
Renaissance Technologies LLC
114.10K
1.63%
-14.00K
-10.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
76.73K
1.1%
+20.28K
+35.91%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
72.67K
1.04%
--
--
Mar 31, 2025
Race (Geoffrey)
51.32K
0.73%
--
--
Mar 31, 2025
Kupfer (David J)
23.94K
0.34%
--
--
Mar 31, 2025
Apella Wealth
20.63K
0.29%
+20.63K
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Date
Type
Ratio
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
